Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Weight loss through lifestyle changes is recommended for nonalcoholic fatty liver disease (NAFLD). However, its efficacy in patients with type 2 diabetes is unproven. RESEARCH DESIGN AND METHODS: Look AHEAD (Action for Health in Diabetes) is a 16-center clinical trial with 5,145 overweight or obese adults with type 2 diabetes, who were randomly assigned to an intensive lifestyle intervention (ILI) to induce a minimum weight loss of 7% or a control group who received diabetes support and education (DSE). In the Fatty Liver Ancillary Study, 96 participants completed proton magnetic resonance spectroscopy to quantify hepatic steatosis and tests to exclude other causes of liver disease at baseline and 12 months. We defined steatosis >5.5% as NAFLD. RESULTS: Participants were 49% women and 68% white. The mean age was 61 years, mean BMI was 35 kg/m2, mean steatosis was 8.0%, and mean aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were 20.5 and 24.2 units/l, respectively. After 12 months, participants assigned to ILI (n = 46) lost more weight (−8.5 vs. −0.05%; P < 0.01) than those assigned to DSE and had a greater decline in steatosis (−50.8 vs. −22.8%; P = 0.04) and in A1C (−0.7 vs. −0.2%; P = 0.04). There were no significant 12-month changes in AST or ALT levels. At 12 months, 26% of DSE participants and 3% (1 of 31) of ILI participants without NAFLD at baseline developed NAFLD (P < 0.05). CONCLUSIONS: A 12-month intensive lifestyle intervention in patients with type 2 diabetes reduces steatosis and incident NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, histological improvement of different MASLD components depended on the amount of weight loss: Whereas about 5-7 % of weight loss already lead to a reduction in liver lipid content in 65 % of people with MASLD, MASH resolution (defined as the absence of hepatocellular ballooning) was achieved in 64 % by a 7-10 % decrease in body weight [46][47][48][49].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [47]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a 12‐month lifestyle intervention program in patients with type 2 diabetes, hepatic steatosis and incident NAFLD was significantly reduced [28].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679 · cited 1×
“Obesity, diabetes, and insulin resistance are the main risk factors for more advanced forms of the disease; up to 70–80% of individuals with NAFLD have insulin resistance or metabolic syndrome (3).”
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154
Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
The Look AHEAD Research Group (2007) · Diabetes Care · doi:10.2337/dc07-0048 · Cited by 1,522
Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., Carucci, P., Musso, A., De Paolis, P., Capussotti, L., Salizzoni, M., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34168 · Cited by 1,439
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Cryptogenic Cirrhosis: Clinical Characterization and Risk Factors for Underlying Disease
Caldwell, S. H., Oelsner, D. H., Iezzoni, J. C., Hespenheide, E. E., Battle, E. H., & Driscoll, C. J. (1999) · Hepatology · doi:10.1002/hep.510290347 · Cited by 1,143
Targher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., Day, C., & Arcaro, G. (2007) · Diabetes Care · doi:10.2337/dc06-2247 · Cited by 992
Adams, L. A., Sanderson, S., Lindor, K. D., & Angulo, P. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.012 · Cited by 911
Cited by
Items 301–366 of 366
Erlich, M. N., Ghidanac, D., Mejía, S. B., Ayoub‐Charette, S., Combe, C. V., Khan, T. A., Ramdath, D. P., Crewson, H., Beck, A., Silva, C. J., et al. (2026) · Nutrients · doi:10.3390/nu18071026 · Cited by 1
PLAKIDA, A. L., Юшковська, О., & Sierpińska, L. E. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i3.113284 · Cited by 1
Fujishima, Y., & Maeda, N. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407869-7.00015-5 · Cited by 1
Nonalcoholic Fatty Liver Disease: Lifestyle Modification
Yoo, K. D., & Jun, D. W. (2014) · Korean Journal of Medicine · doi:10.3904/kjm.2014.86.4.416 · Cited by 1
“거의 대부분의 선행연구에서도 비알코올 지방간 질 환 환자에서 체중 감량은 지방간의 호전을 유도하였다[9,10].”
Plauth, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98368-6.00004-5 · Cited by 1
The Patients at High Risk of Type 2 Diabetes Development
Иванникова, Е. В., & Smirnova, O. M. (2020) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2020-16-26-50-55 · Cited by 1
Rasskazova, M. A., Vorobyev, S. V., & Бутова, Е. Н. (2023) · Terapevticheskii arkhiv · doi:10.26442/00403660.2023.04.202125 · Cited by 1
Treatment of NAFLD: Diet, Physical Activity, and Potential Pharmacological Options
Śliz, J., Popławska, N. A., Skorupska, M., Czeczotka, M. J., Woźniak, K., & Martka, M. M. (2024) · Quality in Sport · doi:10.12775/qs.2024.16.52219 · Cited by 1
“Furthermore, the occurrence of non-alcoholic fatty liver disease was significantly lower compared to a control group following the 12-month intervention period [13].”
BackgroundChen, R., Zhou, Y., Xu, M., Gong, Y., Xia, W., & Yin, X. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005336 · Cited by 1
“39 Thus, controlling these risk factors may reduce the accumulation of fat in the liver, promote liver repair and regeneration, and decrease liver inflammation, which in turn reduces the occurrence of diabetes-related MASLD and MALO.”
Prevalencia de esteatosis hepática no alcohólica en personas diabéticas tipo 2
Murray, A. L., Chaverri, M. E., Madrigal-López, M., & Chacón, C. (2020) · Acta Médica Costarricense · doi:10.51481/amc.v56i1.826 · Cited by 5
Caractérisation du potentiel lipotropique des produits alimentaires d’origine végétale
Fardet, A., Martin, J.-F., & Chardigny, J. (2012) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2012.06.004 · Cited by 1
Medical Approaches to Weight-Centric Management of Obese Patients with Type 2 Diabetes
Ryan, D. H. (2015) · Springer eBooks · doi:10.1007/978-1-4939-3220-7_4 · Cited by 1
George A. Bray, MD: Progress in Obesity—Multidisciplinary Research, Multidimensional Man
Ryan, D. H., HANSEN, B. C., & Cefalu, W. T. (2016) · Diabetes Care · doi:10.2337/dc16-1375 · Cited by 2
McClain, C. J., Smart, L., Safadi, S., & Kirpich, I. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818460-8.00026-5 · Cited by 1
Weiß, J. (2022) · Springer eBooks · doi:10.1007/978-3-662-62484-5_18 · Cited by 1
Mixed lineage kinase 3 connects hepatocellular lipotoxicity with macrophage chemotaxis
Sowa, J., Fingas, C. D., & Canbay, A. E. (2015) · Hepatology · doi:10.1002/hep.28333 · Cited by 1
Effects of treatment of NAFLD on the metabolic syndrome
Yki‐Järvinen, H. (2016) · Wiley eBooks · doi:10.1002/9781118924938.ch21 · Cited by 1
Connor, L., & Fink, S. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-05543-5_15-1
Writers, A. M. (2013) · Drugs & Therapy Perspectives · doi:10.1007/s40267-013-0043-y
Medical complications of diabetes mellitus
Johnson, L. W., & Weinstock, R. S. (2014) · Wiley eBooks · doi:10.1002/9781118887837.ch3 · Cited by 1
Jones, L., & Diehl, A. M. (2010) · Diabetes · doi:10.1002/9781118405550.ch3
Self-citationCurrent and Emerging Therapies for Nonalcoholic Fatty Liver Disease
Gawrieh, S., & Chalasani, N. (2015) · Springer eBooks · doi:10.1007/978-3-319-20538-0_16
Perspectives for managing of nonalcoholic fatty liver disease
Koroy, P., Александрович, С. С., & Yagoda, A. (2015) · Medical news of the North Caucasus · doi:10.14300/mnnc.2015.10075
“Изменение образа жизни и бариатрическая хирургия Модификация образа жизни в виде диеты с уменьшением калорийности пищи и увеличения физической активности является краеугольным камнем в лечении НАЖБП, так как способствует уменьшению активности аминотрансфераз, снижению содержания жира в печени и улучшению проявлений ст…”
Nonalcoholic Fatty Liver Disease and Steatohepatitis
McCarthy, E. M., & Rinella, M. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-24687-1_29
Non-Alcoholic Fatty Liver Disease and Nutrition: A Literature Review
Jafari, S., Hajinasrollah, E., & Foroughi, M. (2016) · Advanced in Food Technology and Nutritional Sciences - Open Journal · doi:10.17140/aftnsoj-2-130
The Look AHEAD Trial: A Review and Discussion of Its
Pi‐Sunyer, X. (2014)
Diabetes and Non‐Alcoholic Fatty Liver Disease
Chitturi, S., & Farrell, G. C. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch51
Fukuhara, K., Yokoyama, T., Sasaki, T., Fujikawa, N., Takadate, T., Miura, T., Yamada, M., & Awabuchi, S. (2017) · Kanzo · doi:10.2957/kanzo.58.14
Hepatocellular Carcinoma in Nonalcoholic Steatohepatitis
Koppe, S., & Arshad, H. M. S. (2017) · Digestive Disease Interventions · doi:10.1055/s-0037-1603572
El-Kader, S. M. A. (2017) · Advanced Research in Gastroenterology & Hepatology · doi:10.19080/argh.2017.03.555608
“Several studies have shown that weight loss is successful in improving liver enzymes, insulin sensitivity, reducing inflammation and liver histology [26-28].”
BackgroundDiagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes
Cusi, K. J. (2017) · Contemporary diabetes · doi:10.1007/978-3-319-61013-9_4
Chopey, I. V., Chubyrko, K. I., Griadil, T. I., & Івачевська, В. В. (2018) · Здобутки клінічної і експериментальної медицини · doi:10.11603/1811-2471.2018.v0.i2.8687
Yarynych, Y. (2018) · Bukovinian Medical Herald · doi:10.24061/2413-0737.xxii.2.86.2018.46
“За оцінками, близько мільярда людей у всьому світі мають НАЖХП [3,4,5,6].”
McClain, C. J., Hill, D. B., & Marsano, L. S. (2012) · Wiley eBooks · doi:10.1002/9781119946045.ch54
Cusi, K. J. (2011) · Endocrine Practice · doi:10.1016/s1530-891x(20)43146-5
Bischoff, S. C., Bernal, W. E., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., Plauth, M., Скрипник, І. М., & Shvets, O. (2021) · Modern Gastroenterology · doi:10.30978/mg-2021-1-59
Jun, D. W. (2013)
유기덕, & Jun, D. W. (2014) · Korean Journal of Medicine
(2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328347aeca
Bourlière, M., & Pol, S. (2019) · Liver International · doi:10.1111/liv.14255
Exercise and training in NAFLD and insulin resistance: psychological approach in humans
Brouwers, B. (2016) · Research Publications (Maastricht University) · doi:10.26481/dis.20160624bb
Connor, L., & Fink, S. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-07209-8_15
Sanyal, A. J. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.726842812.793546732
E-Manuscript Article Summaries
Current Oncology Editorial Office (2011) · Current Oncology · doi:10.3747/co.v18i2.897
Connor, L., & Fink, S. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-05543-5_15-2
Andréelli, F. (2010) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(10)70165-6
Legarreta-Muela, F., Gortáres‐Moroyoqui, P., Arias‐Gastélum, M., Serna-Gutiérrez, A., Ulloa‐Mercado, G., & Mexía, A. M. R. (2022) · KNOW AND SHARE PSYCHOLOGY · doi:10.25115/kasp.v3i3.7088 · Cited by 1
Moore, M. P. (2021) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/91011
Khader, S. G., & Okab, H. F. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns8.12279 · Cited by 2
Nielsen, J. H. (2022) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau495047135
Javadikia, M., Yazdi, A. B., Khajei, R., & abadi, M. R. H. (2023) · Complementary Medicine Journal · doi:10.61186/cmja.12.4.13
Jiwani, R. B., Serra, M. C., Espinoza, S. E., Berndt, A., & Patel, D. I. (2024) · INQUIRY The Journal of Health Care Organization Provision and Financing · doi:10.1177/00469580241248126 · Cited by 1
“23 We also observed improvements in IFN-γ and GM-CSF concentrations, previously reported to exacerbate several inflammatory diseases associated with aging (eg, rheumatoid arthritis).”
BackgroundSmolanka, I., & Sirchak, Y. S. (2025) · Wiadomości Lekarskie · doi:10.36740/wlek/203890
Liu, Z., Jin, P., Liu, Y., Zhang, Z., Wu, X., Weng, M., Cao, S., Wang, Y., Zeng, C., Yang, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26036468
Lu, S., Xie, Q., Kuang, M., Hu, C., Li, X., Yang, H., 盛国太, Xie, G., & Zou, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26574953
Abeysekera, K. W. M., Orr, J. G., Gordon, F. H., Howe, L. D., Hamilton-Shield, J. P., Heron, J., & Hickman, M. (2022) · Figshare · doi:10.6084/m9.figshare.20208307
Zhang, P., Wang, Y.-X., Shen, F.-J., Xing, Y.-F., Gu, J.-Y., Li, X., Jin, H., Jin, S.-F., Xu, M., Wang, H.-J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25440856
Treatment Modalities for Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Review Article
Damle, V. A., Sharma, A., Srivastava, B. K., Raveendran, A. V., Seshadri, K. G., & Mohan, V. (2026) · Journal of Diabetology · doi:10.4103/jod.jod_85_25
Coimbra, F. J. F., de Godoy, A. L., Fernandes, P. H. D. S., Neto, H. F. E. C., Pinheiro, R. N., Boin, I. D. F. S. F., Andraus, W., Tustumi, F., AMARAL, P. C. G., Brandão‐Mello, C. E., et al. (2026) · ABCD Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) · doi:10.1590/0102-672020260000018e1947 · Cited by 1
“…loss on HCC incidence remains to be definitively established, multiple studies have demonstrated that lifestyle interventions, especially those leading to meaningful weight reduction, improve hepatic steatosis and can promote histological resolution of MASLD and regression of fibrosis 73,100,131 .”
Galasso, M., Verde, L., Patrone, R., Ragozzino, G., Annunziata, G., Colao, A., Barrea, L., & Muscogiuri, G. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1855886 · Cited by 2
Wu, J., Zheng, W., Qi, Q., He, C., Zhai, C., & Fan, H. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm51234 · Cited by 1
Chouik, Y., Canivet, C. M., Julla, J., Mouillot, T., Parlati, L., Rouland, A., Smati, S., Tramunt, B., Anty, R., Boursier, J., et al. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.06.013
Swierczek, D., Dreger, M., Jatkowski, J., Kancerek, J., Drozdzowska, B., & Wojnicz, R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177825
“…dietary modification and increased physical activity in patients with type 2 diabetes and a body mass index above 25 kg/m 2 , resulted in an average weight loss of 8%, together with a significant reduction in liver steatosis and the prevalence of MASLD compared with the control group [77].”
Eighty Years After Vague: Advances in Understanding Ectopic Fat and Metabolic Dysfunction
Conte, C., Sumithran, P., le Roux, C. W., Miras, A. D., & Gaal, L. V. (2026) · Obesity Reviews · doi:10.1111/obr.70229
Xu, Z., Liu, Y., Wu, H., Xu, H., & Li, Z. (2026) · Nutrients · doi:10.3390/nu18203394
“In the Look AHEAD ancillary study of 96 adults with type 2 diabetes, 12 months of intensive calorie restriction and physical activity produced a median relative hepatic-fat reduction of 50.8%, versus 22.8% with diabetes support and education [35].”
Influential
Metadata
- Authors
- Lazo, M., Solga, S. F., Horska, A., Bonekamp, S., Diehl, A. M., Brancati, F. L., Wagenknecht, L. E., Pi-Sunyer, F. X., Kahn, S. E., Clark, J. M., & for the Fatty Liver Subgroup of the Look AHEAD Research Group
- Affiliations
- Johns Hopkins University (US)
- Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland;
- Duke Medical Center (US)
- Wake Forest University Health Sciences (US)
- Division of Endocrinology, Diabetes and Nutrition, St. Luke's-Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, New York;
- University of Washington (US)
- Corresponding author
- Lazo, Mariana
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-07-27
- Volume
- 33
- Issue
- 10
- Pages
- 2156-2163
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2945152
- OpenAlex
- W2086657936
- Cited by
- 367
- References
- 24
- Citations by year
- 2026: 17 · 2025: 18 · 2024: 17 · 2023: 18 · 2022: 26 · 2021: 27 · 2020: 31 · 2019: 24 · 2018: 15 · 2017: 17 · 2016: 35 · 2015: 23 · 2014: 26 · 2013: 29 · 2012: 22
- FWCI
- 16.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Johns Hopkins University (M01-RR-00052)
- National Institutes of Health (RR-00052)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK57149, U01DK57149, U01DK057149, P30DK079637, R01DK060427)
- National Center for Research Resources (M01 RR-00052, M01RR000052)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 2 diabetes, non-alcoholic fatty liver disease, hepatic steatosis, intensive lifestyle intervention, weight loss, Look AHEAD trial, 1H NMR, diabetes support and education, glycemic control
- MeSH terms
- Aged, Diabetes Mellitus, Type 2, Fatty Liver, Female, Humans, Life Style, Male, Middle Aged, Weight Loss, Body Mass Index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
